Citizens Jmp Cuts Stryker (NYSE:SYK) Price Target to $400.00

Stryker (NYSE:SYK) had its price target decreased by Citizens Jmp from $440.00 to $400.00 in a research report report published on Monday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the medical technology company’s stock.

A number of other analysts have also issued reports on the company. Robert W. Baird set a $385.00 target price on Stryker in a report on Friday, May 1st. Leerink Partners reduced their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Argus set a $370.00 price objective on Stryker in a research report on Thursday, July 9th. UBS Group assumed coverage on Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price on the stock. Finally, Truist Financial upped their target price on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Up 0.4%

SYK stock opened at $337.41 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The firm has a market capitalization of $129.42 billion, a P/E ratio of 34.97, a P/E/G ratio of 2.14 and a beta of 0.76. Stryker has a 52-week low of $281.00 and a 52-week high of $396.86. The company’s 50 day simple moving average is $318.85 and its 200-day simple moving average is $334.29.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the business posted $3.13 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts anticipate that Stryker will post 15.02 EPS for the current year.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last three months. 4.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. VanderPol Investments L.L.C. raised its stake in shares of Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after acquiring an additional 28 shares during the last quarter. Rossby Financial LCC grew its stake in shares of Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares during the last quarter. KCM Investment Advisors LLC increased its holdings in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC increased its holdings in shares of Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares in the last quarter. Finally, Sompo Asset Management Co. Ltd. raised its position in Stryker by 1.3% in the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 2,390 shares of the medical technology company’s stock worth $946,000 after purchasing an additional 30 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.